---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-109387"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-08-15T23:59:59+00:00"
generated_at: "2026-05-17T12:35:29.048789+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam enters supply agreement with Menarini for obicetrapib products

## Summary
- Supply Agreement dated Aug 12, 2025 with Menarini for obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combo.
- Subsidiary will be exclusive supplier initially; price based on cost of goods sold plus a specified mark-up.
- Parties to initiate manufacturing transfer to Menarini; subsidiary grants non-exclusive license for manufacturing.
- Supply term runs with License Agreement (from June 2022); subsidiary can terminate on 120 days’ notice after transfer or 2 years.
- Either party may terminate for uncured material breach, insolvency, or force majeure exceeding 6 months.

## SEC filing metadata
- accession: 0000950170-25-109387
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017025109387/0000950170-25-109387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017025109387/nams-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-109387
- JSON: https://secwatch.observer/filing/0000950170-25-109387.json
- Plain text: https://secwatch.observer/filing/0000950170-25-109387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.